U.S. Markets close in 1 hr 12 mins

Sequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg

Ladenburg says that while the launch of VisibiliT meets Sequenom's guidance for introduction of a low cost test in 2014, the product is unlikely to have a meaningful impact on the company's financials in the near term. The firm reiterates a Neutral rating on the stock.